Russell Investments Group
MACK

Russell Investments Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Russell Investments Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,111
Closed -$16.4K – 3665
2024
Q1 		$16.4K Buy
1,111
+45
+4% +$632 ﹤0.01% 2796
2023
Q4 		$14.3K Buy
1,066
+202
+23% +$2.55K ﹤0.01% 2785
2023
Q3 		$10.7K Buy
+864
New +$10.5K ﹤0.01% 2985
2019
Q1 		– Sell
-5,974
Closed -$18K – 3126
2018
Q4 		$18K Hold
5,974
– – ﹤0.01% 2870
2018
Q3 		$25K Sell
5,974
-128,833
-96% -$543K ﹤0.01% 2901
2018
Q2 		$521K Sell
134,807
-509
-0.4% -$3.38K ﹤0.01% 2378
2018
Q1 		$857K Buy
135,316
+17,138
+15% +$142K ﹤0.01% 2268
2017
Q4 		$982K Buy
+118,178
New +$1.1M ﹤0.01% 2168

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Russell Investments Group's MACK Position: Q2 2024 in Review

Russell Investments Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 1,111 shares — an estimated $16.4K sold.

Russell Investments Group first reported a position in MACK in Q4 2017 and held it in 8 quarters. The position peaked at $982K in Q4 2017. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Russell Investments Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Russell Investments Group sold 1,111 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $16.4K.
  • Russell Investments Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2017 and held it in 8 quarters.
  • Russell Investments Group's Merrimack Pharmaceuticals, Inc. position peaked at $982K in Q4 2017.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Russell Investments Group's 13F filing for Q2 2024, filed 8 Aug 2024.